Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Total Non-Current Liabilities (2022 - 2024)

LENZ Therapeutics (LENZ) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $11.2 million as the latest value for Q4 2024.

  • Quarterly Total Non-Current Liabilities changed N/A to $11.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Dec 2024, changed N/A year-over-year, with the annual reading at $11.2 million for FY2024, N/A changed from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $11.2 million at LENZ Therapeutics, up from $8.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $62.9 million in Q2 2023, with the low at $8.7 million in Q3 2024.
  • Average Total Non-Current Liabilities over 3 years is $26.4 million, with a median of $16.0 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities soared 289.41% in 2023, then crashed 85.97% in 2024.
  • Over 3 years, Total Non-Current Liabilities stood at $14.8 million in 2022, then skyrocketed by 320.56% to $62.2 million in 2023, then plummeted by 81.96% to $11.2 million in 2024.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $11.2 million, $8.7 million, and $9.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.